Neuropsychiatry

Impaired self-awareness is a frequent and impactful consequence of traumatic brain injury (TBI), occurring in as many as 40% to 80% of individuals with moderate-to-severe TBI. Deficits in self-awareness can negatively impact goal setting, treatment compliance, and motivation for therapy. Addressing this impairment through targeted interventions can improve rehabilitation outcomes, psychosocial adjustment, and community participation.

Experts unpack benzodiazepines in seniors: Beers Criteria, fall risk, Alzheimer bias, and practical low-dose, mindful prescribing strategies.

FDA clears a Parkinson disease wearable and fast-tracks ecopipam for pediatric Tourette syndrome, showing advances in neuropsychiatric care.

FDA approves PET imaging agent for Alzheimer disease tau pathology.

Explore new consensus guidelines on childhood stuttering, uniting psychiatry and neurology with practical treatment insights to improve patient care.

STARS experts redefine stuttering as a brain-based neuropsychiatric disorder, urging interdisciplinary care and warning dopamine-boosting ADHD or antidepressant meds may worsen symptoms.

Concussion recovery in teen athletes often masks anxiety or depression; learn warning signs, screening tips, and safer return-to-play steps.

New BEST teletraining helps people after TBI name emotions, reduce anxiety and anger, and boost resilience—early trials show promise.

New data show APOE4 worsens early sleep disruption in Alzheimer models; CN-105 and zolpidem restore deep sleep and may slow amyloid buildup.

Explore the brain’s 5 monoamines—beyond serotonin and dopamine—revealing histamine, melatonin, and trace amines shaping sleep, appetite, and mood.

Blood exosomal microRNA markers reveal oxidative-stress subtypes, predict psychosis conversion, and guide early, targeted treatments like MitoQ.

Phase 2 MINDFuL data show XPro trends toward cognitive and biomarker gains in inflammation-defined mild Alzheimer disease, with no ARIA, guiding phase 3 plans.

Anosognosia drives untreated schizophrenia into homelessness and jail. Here's why civil care fails and how structured treatment can decrease the number of arrests.

Learn how genetics shape psych med response and dosing.

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.

FDA approves Axsome’s AXS-05 for Alzheimer’s agitation, backed by multiple trials.

Interim analysis suggests tazbentetol may regrow synapses, improving cognition and schizophrenia symptoms.

Spot ICU delirium early with MD‑MOSAIC—an exam for ventilated patients that sharpens diagnosis, prevents harm, and improves outcomes.

In this CME article, learn how depression hides in organ failure, transplants, neurologic disease, and hormonal shifts—plus screening tips and safer treatment choices.

Data suggest PBFT02 therapy boosts progranulin and slows neurodegeneration markers in early FTD.

Experts share more on research developments of remternetug for Alzheimer disease.

Shared pathophysiology between Alzheimer disease and autism may expand diagnosis and treatment opportunities.

Explore how sigma‑1 receptors shape ER–mitochondria signaling, calm neuroinflammation, and inspire therapies from fluvoxamine to dextromethorphan.

New data on long-term donanemab treatment.